ad-magea3
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02879760)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad-magea3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03773744 | Phase 1 | Jan 15, 2020 | Turnstone Biologics, Inc. |
| NCT02879760 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | Chiltern International, Turnstone Biologics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Turnstone Biologics, Inc. | For profit | 2 | 2 | 2 | 2016 |
| Chiltern International | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1